PubMed Health⌕ Search

PubMed · 12061670

Does early erythropoietin therapy decrease transfusions in anemia of prematurity?

Abstract

OBJECTIVE: To investigate the effect of early erythropoietin treatment on induction of erythropoiesis and the need for transfusion in Very Low Birth Weight (VLBW) infants with acute neonatal problems. METHODS: The study group consisted of 14 VLBW prematures with gestational ages less than 32 weeks who were given subcutaneous erythropoietin (600 U/kg per week) and oral iron (3 mg/kg per day) during the first 7-8 weeks of their life, while 13 other VLBW prematures that were given placebo constituted the control group. Weekly hematocrit, (Hct) reticulocyte (Ret) values and the volume of blood drawn and transfused were recorded in the both groups. RESULTS: The groups were comparable regarding with birth weights and gestational ages. The volume of the blood drawn (76.8 +/- 42.5 and 37.0 +/- 15.2) was higher and the volume of the transfusions (51.84 +/- 49.30 and 68.84 +/- 41.2) was lower in the study group but the differences between the groups were not significant (p>0.05). The hematocrit, the reticulocyte and the ferritin values were similar in both the groups at the end of the therapy. CONCLUSION: Under the neonatal intensive care circumstances of developing countries where blood volumes needed for laboratory analysis are still very high, phlebotomy losses can not be avoided. Thus early erythropoietin and iron therapy at these doses are not effective in decreasing the need for transfusion and induction of endogenous erythropoiesis.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Begüm Atasay, Ayla Günlemez, Nejat Akar, Saadet Arsan. 2002. Does early erythropoietin therapy decrease transfusions in anemia of prematurity?. https://doi.org/10.1007/bf02722624

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Efficacy, recovery, and safety of RBCs from autologous placental blood: clinical experience in 52 newborns.

BACKGROUND: In the present study, the efficacy, recovery, and safety of RBCs from autologous placental blood (PB-RBCs) were investigated. STUDY DESIGN AND METHODS: A total of 52 newborns received transfusion with PB-RBCs. The number of newborns requiring no additional allogeneic RBCs was calculated. In 22 of these 52 neonates with a birth weight of 1000 to 2500 g, vital measures were performed during transfusion, and serum potassium levels were measured up to 3 days after transfusion. The results were compared with those of a matched control group given allogeneic RBC transfusions. RESULTS: All neonates of the study group with a birth weight of less than 1000 g, but only 59 percent those with a birth weight of 1000 to 2500 g and 58 percent of those requiring surgery directly after delivery needed allogeneic transfusions in addition to PB-RBCs. The mean Hb increase after RBC transfusion of 10 mL per kg of body weight was 3 g per dL per kg of body weight in both groups; the Hb decrease was accelerated in the placental blood group (0.32 vs. 0.24 g/dL/day; p < 0.05). There were no intergroup differences in the vital parameters. CONCLUSION: Our results show no difference in efficacy and safety between PB-RBC transfusion and allogeneic RBC transfusion. According to well-defined criteria, 40 percent of anemic neonates can be supported by autologous placental blood transfusions alone.

Anemia, Neonatal↗